Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tyrosine aminotransferase is a **pyridoxal phosphate-dependent enzyme** primarily found in the liver, where it catalyzes the first step in the catabolic pathway of the amino acid tyrosine. The enzyme converts **L-tyrosine and 2‑oxoglutarate into 4‑hydroxyphenylpyruvate and L-glutamate**, a reaction essential for proper amino acid degradation and nitrogen balance. Structurally, it is a dimeric protein with each subunit containing an active site lysine residue that forms a Schiff base with its PLP cofactor, which is critical for its transaminase activity. The enzyme belongs to the aminotransferase superfamily, sharing conserved catalytic residues with other family members such as aspartate aminotransferases. Its carboxyl terminus contains glutamate-rich segments resembling PEST sequences, contributing to its rapid turnover rate within cells. Deficiency or dysfunction can lead to metabolic disorders such as type II tyrosinemia due to impaired breakdown of tyrosine[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tyrosine aminotransferase (TAT).